Skip to content

Nasal Naloxone for Narcotic Overdose

Nasal Naloxone for Narcotic Overdose

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01912573
Enrollment
236
Registered
2013-07-31
Start date
2013-09-30
Completion date
2015-03-31
Last updated
2013-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Overdose

Keywords

heroin, prescription pain killers, narcotics

Brief summary

The goal of this study is to determine if nasal naloxone is inferior to standard care for naloxone administration in a pre-hospital setting. Ambulance squads in Adams, Clermont, and Scioto counties in southern Ohio will be randomized to provide either standard care or nasal (IN) naloxone as the initial response to a suspected opioid overdose. Standard care includes administration of naloxone by intravenous (IV), intramuscular (IM) or intraosseus (IO) methods.

Detailed description

This is a randomized, prospective trial that will compare clinical outcomes for parenteral naloxone according to the standard of care (TAU; administration via intravenous \[IV\], intramuscular \[IM\] or intraosseus \[IO\] delivery) versus intranasal \[IN\] for the prehospital emergency treatment of suspected opioid overdose. Ambulance squads in Adams, Clermont, and Scioto counties in southern Ohio will be randomized to administer either standard care or IN naloxone as the initial response to a suspected opioid overdose.

Interventions

DRUGIntranasal (IN) naloxone
DRUGIntraosseus (IO) naloxone

Sponsors

Judith Feinberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presence of hyperventilation or respiratory arrest OR * EMS assessment that the person needs naloxone for possible opioid or unknown drug overdose

Exclusion criteria

* EMS assessment that the participant is less than 12 years old

Design outcomes

Primary

MeasureTime frame
Proportion of patients with adequate respiration within 10 minutes10 minutes after intervention administration

Secondary

MeasureTime frameDescription
Time to first naloxone administrationat baselineTime between emergency call and administration of naloxone.
Opioid Withdrawal Symptomsbaseline
Naloxone Adverse Events3 hours
Number of patients requiring second dose of naloxonewithin 10 minutes of initial dose
Days of hospitalization following naloxone administration7 days
Mortality rate7 days
Proportion of Patients breathing unassisted upon arrival to the hospitalwithin 1 hour

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026